Sorrento Therapeutics, Inc. SRNE
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -4.62% | -42.40% | -33.74% | -38.87% | -- |
| Total Depreciation and Amortization | 7.63% | 5.67% | 6.28% | 7.88% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.99% | 83.99% | 43.38% | 51.22% | -- |
| Change in Net Operating Assets | 2,375.39% | 805.03% | 2,591.97% | 762.31% | -- |
| Cash from Operations | 26.59% | 18.03% | -4.27% | -18.80% | -- |
| Capital Expenditure | 1.12% | -17.74% | -53.95% | -21.30% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 62.84% | 138.32% | -767.90% | 157.33% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.88% | -107.32% | -109.30% | -130.02% | -- |
| Cash from Investing | 5.07% | -119.31% | -135.72% | -136.37% | -- |
| Total Debt Issued | 90.02% | -11.55% | 99.92% | 147.14% | -- |
| Total Debt Repaid | 41.25% | -37.04% | -119.85% | -13.94% | -- |
| Issuance of Common Stock | -58.84% | -20.38% | 85.75% | 61.71% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -24.37% | -37.51% | 71.90% | 261.47% | -- |
| Foreign Exchange rate Adjustments | 19.17% | -270.17% | -381.61% | -656.35% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 91.42% | -205.73% | 34.18% | 138.48% | -- |